Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail

Plus, news on: EpimAb, Boehringer and Nxera, Syneron, Amphix Altimmune goes to Phase 3 in MASH: The drug developer's Phase 2 trial of pemvidutide, a GLP-1/glucagon agonist, failed in June. But based on a longer ...